Cargando…

Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepato...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Tian, Yu, Yang, Zhang, Jing, Li, Haonan, Weng, Qiqing, Jiang, Shuo, Tian, Song, Xu, Tonghao, Hu, Sha, Yang, Guizhi, Zhang, Yan, Wang, Weixuan, Wang, Lexun, Zhu, Qing, Rong, Xianglu, Guo, Jiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457150/
https://www.ncbi.nlm.nih.gov/pubmed/33576035
http://dx.doi.org/10.1002/hep.31749
_version_ 1784571023046213632
author Lan, Tian
Yu, Yang
Zhang, Jing
Li, Haonan
Weng, Qiqing
Jiang, Shuo
Tian, Song
Xu, Tonghao
Hu, Sha
Yang, Guizhi
Zhang, Yan
Wang, Weixuan
Wang, Lexun
Zhu, Qing
Rong, Xianglu
Guo, Jiao
author_facet Lan, Tian
Yu, Yang
Zhang, Jing
Li, Haonan
Weng, Qiqing
Jiang, Shuo
Tian, Song
Xu, Tonghao
Hu, Sha
Yang, Guizhi
Zhang, Yan
Wang, Weixuan
Wang, Lexun
Zhu, Qing
Rong, Xianglu
Guo, Jiao
author_sort Lan, Tian
collection PubMed
description BACKGROUND AND AIMS: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. APPROACH AND RESULTS: We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. CONCLUSION: Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.
format Online
Article
Text
id pubmed-8457150
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84571502021-09-27 Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway Lan, Tian Yu, Yang Zhang, Jing Li, Haonan Weng, Qiqing Jiang, Shuo Tian, Song Xu, Tonghao Hu, Sha Yang, Guizhi Zhang, Yan Wang, Weixuan Wang, Lexun Zhu, Qing Rong, Xianglu Guo, Jiao Hepatology Original Articles BACKGROUND AND AIMS: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. APPROACH AND RESULTS: We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. CONCLUSION: Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH. John Wiley and Sons Inc. 2021-08-26 2021-08 /pmc/articles/PMC8457150/ /pubmed/33576035 http://dx.doi.org/10.1002/hep.31749 Text en © 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Lan, Tian
Yu, Yang
Zhang, Jing
Li, Haonan
Weng, Qiqing
Jiang, Shuo
Tian, Song
Xu, Tonghao
Hu, Sha
Yang, Guizhi
Zhang, Yan
Wang, Weixuan
Wang, Lexun
Zhu, Qing
Rong, Xianglu
Guo, Jiao
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
title Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
title_full Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
title_fullStr Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
title_full_unstemmed Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
title_short Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
title_sort cordycepin ameliorates nonalcoholic steatohepatitis by activation of the amp‐activated protein kinase signaling pathway
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457150/
https://www.ncbi.nlm.nih.gov/pubmed/33576035
http://dx.doi.org/10.1002/hep.31749
work_keys_str_mv AT lantian cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT yuyang cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT zhangjing cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT lihaonan cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT wengqiqing cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT jiangshuo cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT tiansong cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT xutonghao cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT husha cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT yangguizhi cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT zhangyan cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT wangweixuan cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT wanglexun cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT zhuqing cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT rongxianglu cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway
AT guojiao cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway